Interestingly, expression of TCF7, a predictive marker for successful immunotherapy and patient survival (33, 34), was only significantly and strongly downregulated in HER2-CAR T cells, but not in TRX1-expressing HER2-CAR T cells, when cocultured with tumor cells. The gene discussed is ERBB2; the disease is neoplasm.